trastuzumab deruxtecan,sacituzumab
gilead sciences,daiichi sankyo,astrazeneca
['breast', 'sacituzumab', 't-dxd', 'bcsm', 'destiny,breast,2', 'destiny,breast,4', 'tropics-02']
preparing for the presentation of the pro data of the destiny breast-04 study. glad that both tropics-02 and destiny-04 pro data are presented side by side. it is important to understand the patient's perspective differences between t-dxd and sacituzumab. #esmo22 #bcsm 
MD Anderson Cancer Ctr, Breast Med Oncologist, Section Chief of Translational Breast Cancer Research, Executive Director of IBC Program